Figure 10.Correlation between drug sensitivity and prognostic risk scores. Low-risk patients were sensitive to 5-fluorouracil (A), cisplatin (B), gemcitabine (C), irinotecan (D), oxaliplatin (E), and paclitaxel (F). High-risk patients were sensitive to selumetinib (G) and trametinib (H).
